2026-09-30 10:31:00 UTC#390546newconfirmednews
CMPS stock news
CMPS stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-09-23 19:42:07 UTC#358071updateconfirmednews
COMPASS Pathways confirms COMP360 Phase III durability, Q4 NDA filing, and 2027 launch readiness
2026-09-23 07:15:01 UTC#353751newconfirmednews
COMPASS Pathways reports positive Phase III COMP360 data, plans rollout via 8,500 SPRAVATO sites
2026-09-17 16:53:19 UTC#328868duplicateconfirmednews
COMPASS Pathways reaffirms Q4 2026 FDA submission and H1 2027 launch target for COMP360 in TRD
quartrimportance 0.30trust 0.50COMPASS Pathways plc +0.50COMP360 +0.50Janssen Pharmaceuticals, Inc. -0.20
2026-09-16 17:18:43 UTC#322360duplicateconfirmednews
COMPASS Pathways (CMPS) psychedelic therapy COMP360 nears FDA approval, H1 2027 launch targeted
quartrimportance 0.30trust 0.50COMPASS Pathways plc +0.60Food and Drug Administration +0.40COMP360 +0.60
2026-09-16 16:25:10 UTC#322128updateconfirmednews
COMPASS Pathways (CMPS) reports positive Phase III data for COMP360 in TRD, targets early 2027 launch
quartrimportance 0.60trust 0.60COMPASS Pathways plc +0.60Food and Drug Administration +0.30Spravato +0.20
2026-09-15 20:21:29 UTC#316665newconfirmednews
COMPASS Pathways (CMPS) targets Q4 2026 FDA submission for COMP360, expects H1 2027 launch
2026-08-07 10:51:00 UTC#144204newconfirmednews
H.C. Wainwright & Co. cuts Compass Pathways (CMPS) price target to $65 from $70
2026-08-06 17:55:00 UTC#139279newconfirmednews
Morgan Stanley maintains Overweight on Compass Pathways, raises price target to $18 from $17
2026-08-05 19:34:42 UTC#132204updateconfirmednews
COMPASS Pathways targets H1 2027 launch for COMP360, confirms Q4 NDA submission
2026-08-05 19:01:23 UTC#132072duplicateconfirmednews
Compass Pathways Q2 2026 Update: $433M Cash Runway and COMP360 NDA Submission on Track for Q4 2026
2026-08-05 10:38:27 UTC#128987newconfirmednews
COMPASS Pathways Reports Q2 2026 GAAP EPS of -$1.88
2026-08-05 10:31:00 UTC#129043newconfirmeddata release
COMPASS Pathways Reports Q2 EPS of -$1.88 and Operating Loss of $52.37 Million
2026-08-05 10:30:00 UTC#129156duplicateconfirmedpress release
Compass Pathways Q2 2026 results confirm $433M cash position; COMP360 NDA submission expected in Q4
2026-08-05 10:30:00 UTC#129148duplicateconfirmednews
COMPASS Pathways reports Q2 2026 GAAP loss per share of $1.88
2026-08-05 10:30:00 UTC#129147duplicateconfirmednews
COMPASS Pathways reports Q2 2026 net loss of $253.8 million
2026-08-04 15:52:06 UTC#124281newforecastanalysis
COMPASS Pathways Q2 2026 Earnings Preview
2026-07-29 10:58:00 UTC#93492newconfirmedpress release
Compass Pathways to report Q2 2026 financial results on August 5, 2026
2026-07-27 12:52:00 UTC#81979newconfirmednews
Wells Fargo initiates Compass Pathways at Equal-Weight with $13.00 price target
2026-07-08 16:44:00 UTC#13604newconfirmednews